FOLH1 and prostate neoplasm: Over the last two decades, PSMA has been investigated as a promising target, showing antitumoral cytotoxic T-lymphocyte response by HLA-A2 restricted PSMA-derived peptides [35,36,37,38], while other in-vitro and in xenograft models studied its immunotherapeutic potential as effective antibody targeting PSMA-expressing prostate tumor cells [39,40,41,42].